- Home
- CSW vs BLTE Comparison
CSW vs BLTE Comparison
Compare CSW & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSW | BLTE |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CSW | BLTE |
|---|---|---|
| Price | $322.01 | $175.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $307.25 | $161.57 |
| AVG Volume (30 Days) | 190.7K | ★ 221.3K |
| Earning Date | 01-29-2026 | 03-16-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.55 | N/A |
| Revenue | ★ $1,004,138,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $41.70 | ★ N/A |
| Revenue Growth | ★ 16.95 | N/A |
| 52 Week Low | $230.45 | $49.00 |
| 52 Week High | $338.90 | $200.00 |
Technical Indicators
Market Signals| Indicator | CSW | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 60.24 | 54.69 |
| Support Level | $256.64 | $175.18 |
| Resistance Level | $279.37 | $192.94 |
| Average True Range (ATR) | 13.36 | 11.51 |
| MACD | 2.41 | 0.08 |
| Stochastic Oscillator | 84.41 | 38.86 |
Price Performance
Historical ComparisonAbout CSW CSW Industrials Inc.
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.